The system on Bench to Bed: NIH funding, Academic labs and translation, Biotech and venture funding, Drug pricing and development cost, Publishing and open access and Research integrity.
Caribou Biosciences is halting development of two off-the-shelf CAR-T cancer therapies, including its Phase 3-ready candidate vispa-cel, and laying off staff due to an inability to secure funding. The company's board is now evaluating strategic alternatives.
Forbion has secured $2.6 billion across two new venture funds.
Shionogi has agreed to acquire biotech firm IntraBio for $2 billion in cash, gaining the marketed rare disease therapy Aqneursa.
Experts in medical history and neuroscience explain why Americans remain vulnerable to unproven health treatments, from snake oil to modern supplements.
Novo Nordisk has entered a collaboration with AI company Anthropic to speed up drug discovery and development.
The biologic drug tozorakimab, which targets interleukin-33, significantly reduced the rate of moderate and severe exacerbations in patients with COPD.
Moonwalk Biosciences has raised $70 million in Series B funding to advance a pipeline of RNA interference drugs for obesity.
A randomized trial found the AI system Prof. Valmed cut diagnosis time by more than half compared to physicians working alone.
Infectious disease biotech Invivyd has appointed board chairman Marc Elia as its new CEO.
The FDA has launched a public request for information to identify challenges and opportunities in developing botanical prescription drugs.
AI drug discovery firm Superluminal Medicines has raised $60 million to advance its first candidate, an oral therapy targeting the MC4R receptor.
A new Commonwealth Fund report details a sharp decline in U.S. drug overdose deaths in 2024, with preliminary 2025 data showing a continued drop.
Nine mid-sized biopharma firms have agreed to participate in a White House-led Medicaid pricing model, linking U.S.
Roche's Genentech will pay DualityBio $45 million upfront for rights to antibody-drug conjugates designed for patients who progress after existing ADC therapy.
Teva Pharmaceuticals has been named the stalking horse bidder to acquire BioXcel Therapeutics' neuroscience portfolio for $57.5 million upfront.
A commentary in Nature Medicine argues that new anti-obesity drugs represent a disruptive innovation requiring health system adaptation.
BioNTech and Genentech ended a trial of their mRNA cancer vaccine after more deaths occurred in the vaccinated group versus the observation group.
The FDA has permitted Juul Labs to sell an updated version of its vaping device, the Juul2, which includes an optional age-verification system.
The FDA approved updated COVID-19 vaccines from Pfizer, Moderna, and Novavax. Moderna also raised $2.6 billion for its cancer drug business.
UCSF researchers mapped 1,800 autism-linked protein interactions, with 87% novel, published Aug. 27 in Science, offering a guide for drug discovery.
The FDA has issued an Emergency Use Authorization for Simparica TRIO to treat New World Screwworm in dogs and puppies.
The Trump administration's recent allocation of nearly $2 billion to faith-based groups for global health foreign assistance signals a shift in the delivery mechanism for health services.
The Trump administration's choice to lead the FDA, Heidi Overton, has been a key figure behind the scenes in shaping the administration's health policies. Her nomination has raised concerns about competing interests.